An efficient cell selection method is crucial to deliver consistent autologous therapy products when the starting material received is highly variable. Whilst a variety of technologies are being adopted in the industry, there are few GMP-compliant options, and these technologies are often manual, semi-automated, and lack commercial viability. In this article, our experts share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, transitioning manual cell therapy production to scalable automated processes is discussed.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center